Real-world appropriateness of imaging severity thresholds in interstitial lung disease clinical trials
Clinical trials have shown the benefit of nintedanib in multiple forms of fibrotic interstitial lung disease (ILD) 1,2 and suggested benefit of pirfenidone in progressive unclassifiable fibrotic ILD. 3 An important inclusion criterion for these studies was fibrosis affecting more than 10% of lung volume on high-resolution CT. This criterion enriched cohorts for patients with more severe disease, who are presumably at greater risk of ongoing progression, but raises the question of whether patients need to meet this criterion for approval and funding of these medications.
Requiring patients to meet this criterion before approval of these treatments will create multiple challenges. First, quantifying fibrosis on high-resolution CT is not a routine clinical measurement and neither radiologists nor clinicians are trained or experienced in producing this estimate outside certain academic institutions. Second, although there is strong correlation between fibrosis scores across radiologists who are working within a single institution, cohorts have reported wide variability in the relative amount of abnormality reported using high-resolution CT fibrosis scores compared with pulmonary function tests. For example, some cohorts suggested that loss of 20-30% in forced vital capacity corresponds to around 10% high-resolution CT fibrosis severity in a variety of ILD subtypes, 4,5 whereas clinical trials have suggested a relatively equivalent severity of each measurement. 1,2 Although methodological differences might account for some variability, it appears likely that radiologists also take different approaches to estimating fibrosis severity. Third, using such a threshold will almost certainly lead to an increased frequency of highresolution CT imaging in patients who have ILD, with the goal of documenting progression of disease beyond a 10% threshold in patients previously just below this severity or to repeat chest imaging when the scan protocol used for a previous CT was inadequate for accurate severity estimation. These extra scans will put greater strain on health-care systems and expose patients with potential for long-term survival to additional radiation.
These issues indicate the need for regulatory bodies and payers to carefully consider whether mandating a specific high-resolution CT-based fibrosis severity threshold is in patients' best interests. Although the intent is understandable from a clinical trial design perspective, there are other ways of measuring disease severity (eg, pulmonary function) that are better standardised and more accessible. In the event that treatment is restricted on this basis, we encourage the authors of these recent trials to provide clear guidance to the radiology community on how to determine these thresholds in a more objective and reproducible manner. 
